Newsletter Tool

Today's Rundown

Humira rings up $20.7B in 2021, but AbbVie still mum on post-biosimilar expectations
Thermo Fisher revenue climbs 22% for 2021, buoyed by product launches and the year’s biggest buyout
Novartis JAKs in rival to Incyte's topical eczema drug after seeing clinical data
Unvaccinated 23 times more likely than boosted to be hospitalized during omicron wave
Gilead to fork over $1.25B, pay 3% royalty on blockbuster Biktarvy in GSK patent settlement
Paragonix's lung transport system completes 4,700-mile, cross-country transplant
DOJ recovers over $5B in healthcare fraud settlements, judgments in 2021
Gilead's CD47 clinical hold expands as CEO O'Day expresses 'sense of urgency' in getting trials back on track
Kindbody hits unicorn status with Vios Fertility Institute acquisition, new leadership additions
How did UCB close its $1.9B deal to buy Zogenix and its key epilepsy drug? SEC filing reveals details
Medtronic's Hugo surgery robot used in first European procedure
Biden revives Cancer Moonshot program to seek 50% drop in cancer death rate by 2047

Featured Story

Humira rings up $20.7B in 2021, but AbbVie still mum on post-biosimilar expectations

By Kevin Dunleavy

With $5.33 billion in sales in the fourth quarter, which exceeded expectations, Humira reached the elusive $20 billion mark in 2021, the company said in its quarterly sales call. As for the future of the megablockbuster, the company said it would provide 2023 guidance later this year.

Thermo Fisher revenue climbs 22% for 2021, buoyed by product launches and the year’s biggest buyout

By Andrea Park

They say you have to spend money to make money, and that definitely proved true for Thermo Fisher Scientific in 2021.

Novartis JAKs in rival to Incyte's topical eczema drug after seeing clinical data

By Nick Paul Taylor

Strike Novartis from the list of rivals to Incyte’s topical eczema drug Opzelura. After getting a look at early clinical data, Novartis has dumped its topical pan-JAK inhibitor CEE321 over an unfavorable risk-benefit profile.

Unvaccinated 23 times more likely than boosted to be hospitalized during omicron wave

By Dave Muoio

New Los Angeles County public health surveillance data reaffirm vaccines and boosters' protection against COVID-19, and particularly against severe illness.

Gilead to fork over $1.25B, pay 3% royalty on blockbuster Biktarvy in GSK patent settlement

By Eric Sagonowsky

GlaxoSmithKline and Gilead Sciences have been duking it out in the HIV arena for years, hoping to get an edge over one another with new launches and head-to-head drug trials. Now, in a Tuesday settlement, the companies are resolving a legal dispute over lucrative patents related to GSK's HIV drug dolutegravir.

Paragonix's lung transport system completes 4,700-mile, cross-country transplant

By Conor Hale

The high-stakes transplant procedure set a new record for the company’s LUNGguard system, pushing past its intended organ storage time of up to eight hours.

DOJ recovers over $5B in healthcare fraud settlements, judgments in 2021

By Dave Muoio

Healthcare settlements and judgements comprised the majority of the over $5.6 billion DOJ recovered in fiscal year 2021.

Gilead's CD47 clinical hold expands as CEO O'Day expresses 'sense of urgency' in getting trials back on track

By Annalee Armstrong

Gilead revealed that a partial clinical hold for its CD47 targeted cancer hopeful is larger than originally thought. Disclosed in the fine print of the pharma giant’s fourth-quarter earnings presentation Tuesday was that two more studies are subject to the hold, bringing the total number of affected trials to seven.

PM Tracker

Featured Story

Humira rings up $20.7B in 2021, but AbbVie still mum on post-biosimilar expectations

Top Stories

Thermo Fisher revenue climbs 22% for 2021, buoyed by product launches and the year’s biggest buyout

Novartis JAKs in rival to Incyte's topical eczema drug after seeing clinical data

Unvaccinated 23 times more likely than boosted to be hospitalized during omicron wave

Gilead to fork over $1.25B, pay 3% royalty on blockbuster Biktarvy in GSK patent settlement

Paragonix's lung transport system completes 4,700-mile, cross-country transplant

DOJ recovers over $5B in healthcare fraud settlements, judgments in 2021

Gilead's CD47 clinical hold expands as CEO O'Day expresses 'sense of urgency' in getting trials back on track

Kindbody hits unicorn status with Vios Fertility Institute acquisition, new leadership additions

How did UCB close its $1.9B deal to buy Zogenix and its key epilepsy drug? SEC filing reveals details

Medtronic's Hugo surgery robot used in first European procedure

Biden revives Cancer Moonshot program to seek 50% drop in cancer death rate by 2047